Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

Emcure becomes first Indian company to commercialise semaglutide 2.4 mg, the second brand of Wegovy®, in India.

The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...

Novo Nordisk's experimental drug, CagriSema, shows promise beyond weight loss, potentially offering significant ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month ...

Two years later, those treatments have thrust Metsera to the centre of a fierce takeover battle, with Ozempic maker Novo Nordisk and Pfizer willing to pay up to $10bn for the company. Both once again ...